Here’s what diabetes tech companies are doing for National Diabetes Awareness Month

As we enter November, we enter National Diabetes Awareness Month. A number of diabetes technology developers plan to mark that in a special way.

Dexcom (Nasdaq:DXCM), Insulet (Nasdaq:PODD) and Embecta (Nasdaq:EMBC) all announced their plans to celebrate.

Last year, a handful of companies marked the month — which includes World Diabetes Day (Nov. 14) — in a series of ways. Here’s how they’re doing it this year.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

7 innovative digital health offerings to treat diabetes

MIT engineers are working on an app that that identifies and quantifies food content, which can aid in carbohydrate counting for people with diabetes. [Image from MIT News] From using your smartphone to track data to reversing your diabetes altogether, these digital health technologies stand out.

Advances in treatments for diabetes never stop coming. Whether that be in the form of insulin pumps or continuous glucose monitors, we’ve seen plenty.

Moving away from the physical device, innovations in the digital diabetes space continue to impress. Digital therapeutics, artificial intelligence- and cloud-based offerings and more comprise an intriguing list of technologies.

Here are seven digital offerings aimed at treating diabetes that you might want to keep an eye on:

1. Digital therapeutics for diabetes

Digital therapeutics is an ever-growing space capable of treating a range of diseases and conditions. That reach extends to diabetes, as shown by companies…

Read more
  • 0

Dexcom focuses on early diabetes diagnosis as COVID links emerge

Dexcom VP of Global Clinical Initiatives Tomas Walker [Photo courtesy of Dexcom]New evidence is showing that COVID-19 may increase a person’s risk of diabetes, but it could be years until we know for sure.

In the meantime, Dexcom (Nasdaq:DXCM) is getting ready, VP of Global Clinical Initiatives Tomas Walker said.

Walker recently spoke with Medical Design & Outsourcing to discuss the San Diego-based diabetes device developer’s proactive approach to chronic COVID-19 conditions, technology that can help diagnose new cases, and the likelihood that particular devices and components will be in greater demand in the years ahead.

Get the full story at our sister site, Medical Design & Outsourcing.

Read more
  • 0

Dexcom focuses on early diabetes diagnosis as COVID links emerge

Dexcom VP of Global Clinical Initiatives Tomas Walker [Photo courtesy of Dexcom]

New data is showing that COVID-19 may increase a person’s risk of diabetes, but it could be years until we know for sure.

In the meantime, Dexcom (Nasdaq:DXCM) is getting ready, VP of Global Clinical Initiatives Tomas Walker said.

Walker recently spoke with Medical Design & Outsourcing to discuss the San Diego-based diabetes device developer’s proactive approach to chronic COVID-19 conditions, technology that can help diagnose new cases, and the likelihood that particular devices and components will be in greater demand in the years ahead.

The following has been lightly edited for space and clarity.

MDO: How does the SARS-CoV-2 virus and its COVID-19 disease affect the pancreas?

Walker: In February, March of 2020, there were a couple of papers published out of China very early in the expe…

Read more
  • 0

MIT team working on all-in-one diabetes management devices

MIT engineers are working on an app that that identifies and quantifies food content, which can aid in carbohydrate counting for people with diabetes. [Image from MIT News]MIT researchers are touting a platform aimed at helping patients maintain healthy glucose levels by streamlining the diabetes management process.

The researchers say the steps of estimating the carbohydrate content of a meal, drawing blood to measure blood glucose levels, then calculating the proper insulin dose before injecting the insulin — which typically must be repeated for every meal — make it difficult to maintain a treatment regimen. Those researchers say they’ve developed a new approach that makes the process easier and more efficient while helping diabetes patients maintain their healthy glucose levels.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Walmart teams up with Novo Nordisk to launch private-brand analog insulin 

Walmart (NYSE:WMT) is launching what it describes as the first private label analog insulin. The company estimates the insulin products will save customers between 58% and 70% of the cost of branded insulin.

Novo Nordisk (NYSE:NVO) will manufacture the analog insulin, which is a type of lab-grown insulin genetically engineered to optimize glucose control. The retail price of analog insulin vials will be $72.88, while a FlexPen insulin pen will cost $85.88. Walmart has concluded that the per-unit savings of the products will be $101 per vial and $251 per insulin pen, respectively.

The insulin will only be available through Walmart’s ReliOn brand of diabetes products.

Get the full story from our sister site, Drug Delivery Business.

Read more
  • 0

Study shows CGMs better at controlling blood sugar in type 2 diabetes

Kaiser Permanente touts a study demonstrating that using continuous glucose monitors offers better blood sugar control for patients with type 2 diabetes.

Patients with insulin-treated type 2 diabetes using continuous glucose monitors (CGMs) typically had better blood sugar control and fewer visits to the emergency room for hypoglycemia, the study found. The study was published yesterday in JAMA and was supported by an independent investigator award from Dexcom and funding from the National Institute of Diabetes and Digestive and Kidney Diseases.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

FDA issues draft clinical trial guidelines for neurostim, other devices to treat diabetes

The FDA today issued a draft guidance with recommendations for clinical trials for certain devices intended for treating diabetes.

Included in the guidance are recommendations for feasibility and early feasibility clinical studies for certain medical devices intended to therapeutically improve glycemic control in patients with type 2 diabetes mellitus, independent of medication delivery, according to a news release.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Insulet shares fall on mixed Q1 results

Insulet (NSDQ:PODD) shares fell 4% today on break-even first-quarter results that were lower than analysts’ expectations. The company, however, raised the low end of its revenue guidance range to 16% to 20%. The range was previously 15–20%.

The Acton, Mass.-based wearable insulin delivery system developer posted a net loss of $0.0 million, or 0¢ per diluted share, on sales of $246.1 million for the three months ended March 31. For the sake of comparison, the company had a net loss of $2.1 million, or $(0.03) per diluted share, in the same quarter of 2020.

Adjusted to exclude one-time items, earnings per share were $0.00. Analysts were looking for EPS of $0.08 on sales of $247.1 million.

Get the full story from our sister site, Drug Delivery Business. 

Read more
  • 0

Novo Nordisk to test oral semaglutide as an obesity therapy

Global pharma firm Novo Nordisk (NYSE:NVO) will launch a Phase 3a study to investigate the potential of oral Ozempic (semaglutide) to treat obesity. 

The drug is currently indicated in a subcutaneous form in the U.S. for people with type 2 diabetes to improve glycemic control in conjunction with diet and exercise and to lower diabetics’ risk of major adverse cardiovascular events. 

The most recent Phase 3a trial will test an oral 50-mg dose of the drug with roughly 1,000 volunteers who are obese or overweight with comorbidities. 

The company anticipates that the 68-week study will kick off in the second half of 2021. 

Recent clinical trial results indicate that subcutaneous semaglutide paired with behavioral therapy can support weight loss. 

Novo Nordisk has also filed a new drug application with the FDA for a 2.4-mg dose of subcutaneous semaglutide for chronic weight management. The company is seeking a similar indication in the European m…

Read more
  • 0

Once-a-week insulin dosing shows promise in studies

[Image from Mykenzie Johnson on Unsplash]Studies suggest that a new once-per-week injectable insulin therapy is safe and as effective as daily injections for those with type 2 diabetes.

Two international clinical trials published today in Diabetes Care found that the once-weekly treatment has the potential to offer a convenient alternative to daily insulin shots for those with type 2 diabetes, according to a news release.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Once-a-week insulin dosing shows promise in studies

[Image from Mykenzie Johnson on Unsplash]Studies suggest that a new once-per-week injectable insulin therapy is safe and as effective as daily injections for those with type 2 diabetes.

Two international clinical trials published today in Diabetes Care found that the once-weekly treatment has the potential to offer a convenient alternative to daily insulin shots for those with type 2 diabetes, according to a news release.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0